Adx-324

Hereditary Angioedema

ADARx Pharmaceuticals, Inc.Phase 3Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 89/ 100

Competitive context

16 Active assets in the Hereditary Angioedema cohort.

Asset / Sponsor	Phase	Rating
Firazyr Nang Kuang Pharmaceutical Co., Ltd.	Phase 4	A
Sebetralstat KalVista Pharmaceuticals, Ltd.	Phase 4	A
Firazyr Nang Kuang Pharmaceutical Co., Ltd.	Phase 4	A
Berotralstat BioCryst Pharmaceuticals	Phase 3	A
Lanadelumab Takeda	Phase 3	A

View all 37 →

Same molecule, other indications

Adx-324 is also rated in:

HAEDormant

BB

Indicative ·

66 / 100

hereditary angioedema type 1Dormant

B

Indicative ·

60 / 100

hereditary angioedema type 2Dormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.